Search results
Sep 24, 2024 · “Secondary progressive multiple sclerosis is characterized by insidious worsening of disability over time, independent of relapses, and represents a critical unmet need because we don’t have effective treatments,” said Robert Fox, MD, Vice Chair of Research at the Cleveland Clinic’s Neurologic Institute, Chair of the HERCULES Glboal ...
6 days ago · “Secondary progressive multiple sclerosis is characterized by insidious worsening of disability over time, independent of relapses, and represents a critical unmet need because we don’t have effective treatments,” said Robert Fox, MD, Vice Chair of Research at Cleveland Clinic’s Neurological Institute and Chair of the HERCULES Global ...
Sep 20, 2024 · Robert Fox, MD Vice Chair of Research at Cleveland Clinic’s Neurological Institute, Cleveland, Ohio and Chair of the HERCULES Global Steering Committee “Secondary progressive multiple sclerosis is characterized by insidious worsening of disability over time, independent of relapses, and represents a critical unmet need because we don’t ...
Sep 20, 2024 · Robert I. Fox, MD, PhD, FACP, summarizes the data presented at the 2005 ACR meeting regarding recent understanding of the innate immune system.
Oct 3, 2024 · Presented at the 2024 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress, September 18-20, in Copenhagen, Denmark, by lead author Robert J. Fox, MD, and colleagues, the study randomized 467 patients with primary progressive MS (35.2%), non-active secondary progressive MS (59.5%) and active secondary ...
Sep 22, 2024 · “The company developing the medication asked us if we could design the study for them,” says Robert Fox, MD, a neurologist with Cleveland Clinic’s Mellen Center for Multiple Sclerosis Treatment and Research and the study’s principal investigator. “We decided to take them up on the offer, and they ultimately asked us to conduct the ...
Sep 20, 2024 · Positive results from the HERCULES phase 3 study in people with non-relapsing secondary progressive multiple sclerosis (nrSPMS) demonstrated that tolebrutinib delayed the time to onset of 6-month confirmed disability progression (CDP) by 31% compared to placebo (HR 0.69; 95% CI 0.55-0.88; p=0.0026). Further analysis of secondary endpoints ...
